2-(4-(1-methyl-1H-imidazol-2-yl)benzyloxy)nicotinamide | 1580504-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-(1-methyl-1H-imidazol-2-yl)benzyloxy)nicotinamide
• 英文别名: 2-[[4-(1-Methylimidazol-2-yl)phenyl]methoxy]pyridine-3-carboxamide；2-[[4-(1-methylimidazol-2-yl)phenyl]methoxy]pyridine-3-carboxamide
• CAS: 1580504-37-5
• 化学式: C₁₇H₁₆N₄O₂
• 分子量: 308.34
• InChiKey: APRPXNUMJFONHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl 4-(1-methyl-1H-imidazol-2-yl)benzoate 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 paraffin oil 为溶剂， 反应 3.84h， 生成 2-(4-(1-methyl-1H-imidazol-2-yl)benzyloxy)nicotinamide
  参考文献：
  名称：

  Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of Mycobacterium tuberculosis

  摘要：

  A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 mu M as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clinical isolates, which indicate that the compounds could be acting through a novel mode of action.

  DOI：

  10.1021/ml4004815

文献信息

• Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of <i>Mycobacterium tuberculosis</i>
  作者：Chaitanya Kumar Kedari、Nilanjana Roy Choudhury、Sreevalli Sharma、Parvinder Kaur、Supreeth Guptha、Manoranjan Panda、Kakoli Mukerjee、Vasanthi Ramachandran、Balachandra Bandodkar、Sreekanth Ramachandran、Subramanyam J. Tantry

  DOI：10.1021/ml4004815

  日期：2014.5.8

  A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 mu M as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clinical isolates, which indicate that the compounds could be acting through a novel mode of action.